The N-of-1 Batch Strategy: What It Demands From Your CDMO Partner
FDA Regulatory Strategy · CDMO Partner Selection · Ultra-Rare Disease Manufacturing
Why Your CDMO Choice Matters More Than Ever
Are you currently working on a gene therapy for a rare or ultra-rare disease that affects only a small percentage of patient population with severe genetic conditions or predisposition to genetic mutations which are difficult to treat. Big CDMOs won’t return your calls. The traditional 3-batch PPQ model would cost $5-12M - more than your entire budget - and months of validation you can’t afford to wait through.
The FDA has now put it in writing: there is no minimum number of PPQ lots. Process validation is a BLA-stage expectation, not an IND one - and how much you do is risk-based and negotiated program by program. For ultra-rare programs, that’s what makes the N-of-1 path a real option - fewer lots, less time in validation, and a faster route to BLA and to patients, with far less capital tied up along the way - if you choose a CDMO partner having the complete ecosystem with clinical pathway understanding, extensive drug development experience and regulatory exposure.
Who this page is for:
N-of-1 in 30 Seconds: Why It Changes CDMO Selection
Traditional approach (industry default)
Many programs are still asked to run 3 full-scale commercial batches - an industry default, not a regulatory requirement - to validate your manufacturing process. For an ultra-rare gene therapy program (e.g., AAV- or LV-based) with 10-50 patients, the cost alone - $5.4-12.6M - plus months of waiting could make the project commercially and financially unviable before it ever reaches a patient.
N-of-1 approach (risk-based validation)
FDA’s 2026 CMC Flexibilities guidance is explicit: “FDA does not specify a minimum number of PPQ batches in the biologics licensing requirements or CGMP regulations.” The number of lots is justified case by case - and for ultra-rare programs, that often means far fewer lots, a shorter path to BLA, and a faster route to patients. A leaner, well-justified package can also cut validation cost by roughly half (public estimates: 50-67% lower). With concurrent release, your lots can reach patients right after BLA approval - no waiting.
For ultra-rare diseases (n = 1 to n = 100), the N-of-1 approach is often the only path that is both fast enough and affordable enough to ensure the therapy reaches patients.
The Regulatory Foundation: FDA in Their Own Words
Flexibility is also where the speed comes from: you don’t have to complete a fixed 3-batch template before you can move. But this flexibility comes with a condition: the CDMO must possess deep process understanding and platform data to make the N-of-1 case to FDA convincing. That elevates CDMO selection from a “fill and finish” decision to a regulatory partnership decision.
The 5 Demands of N-of-1 - and How CoJourney Delivers
| Demand | What FDA expects | CoJourney’s platform advantage |
|---|---|---|
| 1. Platform knowledge depth | Cross-program data to justify fewer batches | Validated across AAV1,2,5,6,8,9 + engineered serotypes, LV, mRNA; every program feeds the next |
| 2. Batch-to-batch consistency | No room for outliers; high consistency required (industry standard <5% CV) | Achieved through standardized plasmids, stable HEK293 suspension, closed-system bioreactors, PAT monitoring |
| 3. Small-sample analytics | Full characterization from limited volume | SCIEX 8800 (genome integrity), AUC (full/empty), nanoDSF/SEC-MALS (aggregation), NGS (genome) - all low-volume validated |
| 4. Regulatory CMC agility, understanding and know-how | Program- and patient-risk-based PPQ justification; concurrent release; lifecycle specs | Dedicated “PPQ Justification Module”; pre-drafted concurrent release protocols; proactive CBER engagement |
| 5. Speed without compromise | Weeks, not months | Platform SOPs + standardized materials → from plasmid to purified drug substance in weeks, not months |
| 6. Access to the complete ecosystem | One-stop shop and end-to-end solution provider | Proven drug development capabilities of leveraging the complete ecosystem to address any gaps with regards to product and process development with positive clinical outcomes |
By the Numbers: Why N-of-1 Changes the Timeline - and the Economics
| Metric | Value |
|---|---|
| Typical 3-batch PPQ cost (industry default) | $5.4-12.6M |
| N-of-1 PPQ cost (risk-based, reduced-lot package) | $1.8-4.2M (public estimate; 50-67% lower) |
| CoJourney batch consistency (key CQAs) | <5% CV |
| CoJourney turnaround (plasmid → drug substance) | Weeks, not months |
| Platform modalities validated | 7+ AAV serotypes (AAV1, 2, 5, 6, 8, 9 + custom); LV, mRNA |
Why Choose CoJourney for Ultra-Rare Gene Therapy?
Not every CDMO is built for this. CoJourney is.
- We say “yes” to N-of-1 - No minimum batch size that excludes you.
- Speed that matches the urgency - Weeks, not months, from plasmid to drug substance, so your therapy reaches patients sooner.
- Platform knowledge that helps justify fewer lots - Cross-program data across our AAV, LV and mRNA platforms makes the N-of-1 case to FDA convincing.
- Consistency you can prove - One lot, no second chance. Below 5% CV on key quality attributes means your lot works the first time - no re-run, no lost months.
- Analytics built for small samples - Full characterization even from limited material.
- Regulatory CMC expertise - Pre-drafted concurrent release protocols and lifecycle specs, with proactive FDA engagement.
- Flexible partnership models - From fee-for-service to risk-sharing with backend upside.
Is Your Gene Therapy Program Ready for N-of-1? Choose the CDMO That Is.
CoJourney delivers the platform depth, batch consistency, analytical rigor, regulatory agility, and speed that the N-of-1 strategy demands. Let’s discuss how we can support your ultra-rare gene therapy program.
Get a quick and free N-of-1 Feasibility Assessment
48-hour turnaround. Fill out a short form (disease, target patient population, current stage, estimated budget). We’ll reply with whether your program fits N-of-1, estimated PPQ lot count, rough budget and suggested next steps.
Download the Complete N-of-1 Strategy Guide & Toolkit
FDA guidance highlights annotated for ultra-rare developers, a one-page N-of-1 decision tree, CDMO readiness checklist, 1-batch vs 3-batch budget template, and China IIT Guide.
Schedule a 15-Minute Consultation
Our BD team will reach out to confirm your needs, then match you with the right CoJourney expert. No pitch - just a conversation about your program and whether N-of-1 makes sense.
References
FDA. “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application; Guidance for Industry.” Final, May 2026.
FDA. “Human Gene Therapy for Rare Diseases; Guidance for Industry.” Final, Jan 2020.
FDA. “Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.” Draft, Feb 2026.
FDA. “Frequently Asked Questions - Developing Potential Cellular and Gene Therapy Products; Guidance for Industry.” Final, Aug 2026.
This document is for informational purposes. Consult FDA guidance directly and engage with CBER for program-specific regulatory strategy.
